1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Abeona Therapeutics Inc.

Abeona Therapeutics Inc.

ABEO
Abeona Therapeutics Inc.US flagNASDAQ Capital Market
4.59
USD
+0.18
- -
262.22MMarket Cap

Total Valuation

Abeona Therapeutics Inc. carries a market capitalization of 262.22M, placing it among publicly traded companies globally. Its enterprise value stands at 226.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap262.22M
Enterprise Value226.70M

Share Statistics

Abeona Therapeutics Inc. currently has 57.23M shares outstanding.

Shares Outstanding57.23M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Abeona Therapeutics Inc. trades at a trailing price-to-earnings ratio of 8.17. The price-to-sales ratio is 13.55, and the price-to-book ratio stands at 2.76.

PE Ratio8.17
PS Ratio13.55
PB Ratio2.76
P/TBV Ratio2.76
P/FCF Ratio-4.53
P/OCF Ratio-4.53

Enterprise Valuation

EV / Sales8.88
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Abeona Therapeutics Inc. maintains a current ratio of 6.63, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.52, indicating elevated leverage, while an interest coverage ratio of -24.14 demonstrates limited ability to service its debt obligations.

Current Ratio6.63
Quick Ratio6.32
Debt / Equity15.52
Debt / EBITDA-0.25
Interest Coverage-24.14

Financial Efficiency

Return on Equity (ROE)-43.13
Return on Assets (ROA)-29.54
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.37

Taxes

Income Tax-15.41M
Effective Tax RateN/A

Stock Price Statistics

Abeona Therapeutics Inc.'s stock has declined approximately -16.62727% over the past 52 weeks. The 50-day moving average sits at 5.62, while the 200-day moving average is 5.53.

Beta (5Y)N/A
52-Week Price Change-16.62727%
50-Day Moving Average5.62
200-Day Moving Average5.53
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Abeona Therapeutics Inc. generated 25.52M in revenue and converted that into -62.89M in net income, yielding earnings per share of -1.12. EBITDA reached -79.93M, while operating income came in at -83.61M.

Revenue25.52M
Gross Profit15.32M
Operating Income-83.61M
Pretax Income-78.30M
Net Income-62.89M
EBITDA-79.93M
EBIT-83.61M
Earnings Per Share (EPS)-1.12

Balance Sheet

Abeona Therapeutics Inc. holds 146.83M in cash and equivalents against 19.87M in total debt, resulting in a net debt position of -41.24M. Total book value stands at 128.06M, with working capital of 139.77M providing operational flexibility.

Cash & Cash Equivalents146.83M
Total Debt19.87M
Net Debt-41.24M
Equity (Book Value)128.06M
Book Value Per Share2.24
Working Capital139.77M

Cash Flow

Abeona Therapeutics Inc. produced -76.44M in operating cash flow over the past twelve months.

Operating Cash Flow-76.44M
Capital ExpendituresN/A
Free Cash Flow-76.44M
FCF Per Share-1.37

Margins

Abeona Therapeutics Inc. operates with a gross margin of 60.04, reflecting its pricing power and cost economics. The operating margin of -327.64 and net profit margin of -246.42 provide insight into operational efficiency.

Gross Margin60.04
Operating Margin-327.64
Pretax Margin-306.81
Profit Margin-246.42
EBITDA Margin-313.22

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-0.91
FCF Yield-22.10

Stock Splits

Abeona Therapeutics Inc.'s most recent stock split took place on July 5, 2022 with a 25:1 split ratio.

Last Split Date7/5/2022
Split Ratio25:1

Scores

Abeona Therapeutics Inc. posts an Altman Z-Score of -2.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.41